<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6735">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00989235</url>
  </required_header>
  <id_info>
    <org_study_id>IM101-023 LT (Sub study)</org_study_id>
    <secondary_id>Eudrac # 2002-000784-26</secondary_id>
    <nct_id>NCT00989235</nct_id>
  </id_info>
  <brief_title>Substudy - Low Dose of Abatacept in Subjects With Rheumatoid Arthritis</brief_title>
  <official_title>A Phase 3B, Multi-Center, Randomized, Double-blind Study to Evaluate Remission and Joint Damage Progression in Methotrexate-naïve Early Erosive Rheumatoid Arthritis Subjects Treated With Abatacept Plus Methotrexate Compared With Methotrexate - Low Dose Sub-Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Poland: National Institute of Medicines</authority>
    <authority>Russia: Ministry of Health of the Russian Federation</authority>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <authority>Belgium: The Federal Public Service (FPS) Health, Food Chain Safety and Environment</authority>
    <authority>Brazil: National Committee of Ethics in Research</authority>
    <authority>Canada: Health Canada, Biologics and General Therapies Directorate, Regulatory Affairs Division Office of Clinical Trials Therapeutic Products Directorate</authority>
    <authority>Mexico: Federal Commission for Sanitary Risks Protection</authority>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Spain: Spanish Agency of Medicines</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this exploratory sub-study was to evaluate from a clinical perspective the
      impact on disease activity of lowering the dose of abatacept from 10 mg/kg to 5 mg/kg in
      subjects who had achieved remission (Disease Activity Score 28 [DAS 28]-erythrocyte
      sedimentation rate [ESR] &lt; 2.6) at Day 701 of study IM101023.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Time to Disease Relapse Through Month 12 (Kaplan-Meier Cumulative Percentage of Events of Disease Relapse)</measure>
    <time_frame>Months 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>An event of disease relapse was defined as additional Disease-modifying antirheumatic drug (DMARD) therapy given, or 2 or more courses of high steroids given, or return to abatacept 10 mg/kg (rescue medication given), or DAS28 C-reactive protein (CRP) score &gt;=3.2 at 2 consecutive visits. Time to disease relapse was evaluated using life tables (Kaplan-Meier Cumulative Percentage of Events of Disease Relapse).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Disease Relapse</measure>
    <time_frame>After 12 Months of treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Disease relapse is defined as additional DMARD therapy given, or 2 or more courses of high steroids given, or return to abatacept 10 mg/kg (rescue medication given), or DAS28 CRP score &gt;= 3.2 at 2 consecutive visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Time-Matched Baseline DAS28 CRP Scores</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean baseline DAS28 CRP values for the cohort of participants with serum samples available at that timepoint. DAS 28 is a continuous variable which is a composite of 4 variables: number of tender joints out of 28, number of swollen joints out of 28 joints, CRP in mg/L and subject assessment of disease activity measure on a visual analogue scale (VAS) of 100 mm. The DAS28 provides a score on a scale from 0 to 10 indicating the current activity of the rheumatoid arthritis (&gt;5.1=high disease activity; &lt;3.2=low disease activity; &lt;2.6=remission).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Change From Baseline in DAS28 CRP During Double-Blind Treatment</measure>
    <time_frame>Baseline, Days 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, 337, 365</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean baseline DAS28 CRP values for the cohort of participants with serum samples available at that timepoint. DAS 28 is a continuous variable which is a composite of 4 variables: number of tender joints out of 28, number of swollen joints out of 28 joints, CRP in mg/L and subject assessment of disease activity measure on a VAS of 100 mm. The DAS28 provides a score on a scale from 0 to 10 indicating the current activity of the rheumatoid arthritis (&gt;5.1=high disease activity; &lt;3.2=low disease activity; &lt;2.6=remission).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With 2 Consecutive DAS 28 CRP Scores ≥ 3.2 (Loss of Low Disease Activity Status)</measure>
    <time_frame>After 12 months of treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>DAS 28 is a continuous variable which is a composite of 4 variables: number of tender joints out of 28, number of swollen joints out of 28 joints, CRP in mg/L and subject assessment of disease activity measure on a VAS of 100 mm. The DAS28 provides a score on a scale from 0 to 10 indicating the current activity of the rheumatoid arthritis (&gt;5.1=high disease activity; &lt;3.2=low disease activity; &lt;2.6=remission).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Given Additional DMARD Therapy During Double-Blind Treatment</measure>
    <time_frame>After 12 months of treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Additional DMARD therapy is defined as a re-introduction of methotrexate (MTX), an increase of at least 2.5 mg of MTX, or the addition of at least 1 DMARD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who at Any Time During Double-Blind Treatment Were Given 2 or More Courses of High-Dose Steroids</measure>
    <time_frame>After 12 months of treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>A course of high dose steroids is defined as a course of intramuscular, intravenous, or high dose oral corticosteroids (use of &gt; 10 mg/day equivalent of prednisone for a minimum of 3 consecutive days or for those subjects who had continued use for long durations of time, each course was determined by 28 day intervals).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Given Rescue Medication Therapy During Double-Blind Treatment</measure>
    <time_frame>After 12 months of treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>All subjects in the sub-study randomized to receive double-blind abatacept 5 mg/kg or 10 mg/kg. Subjects rescued to open-label treatment received abatacept 10 mg/kg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Modified Therapy During Double-Blind Treatment</measure>
    <time_frame>After 12 months of treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Modified therapy=additional DMARD therapy, 2 or more courses of high dose steroids or rescue medication. Additional DMARD therapy=re-introduction of methotrexate (MTX), an increase of at least 2.5 mg of MTX, or the addition of at least 1 DMARD. A course of high dose steroids=a course of intramuscular, intravenous, or high dose oral corticosteroids (use of &gt; 10 mg/day equivalent of prednisone for a minimum of 3 consecutive days or for those subjects who had continued use for long durations of time, each course was determined by 28 day intervals). Rescue medication=abatacept 10 mg/kg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Lost Remission Status</measure>
    <time_frame>After 12 months of treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Loss of remission is defined as DAS 28 CRP &gt;=2.6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steady-state Trough Serum Concentration (Cmin) of Abatacept During Double-Blind Treatment</measure>
    <time_frame>Day 701 of the main study; sub-study Days 1, 85, 169, 253</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths, and Discontinuations During Double-Blind Treatment</measure>
    <time_frame>From start of substudy up to 56 days post last dose in the double-blind period or start of the open-label rescue period, whichever occurred first until end of study (study duration was 115 weeks)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. Related AE/SAE=Certain, Probable, Possible, or Missing. SAE=any untoward medical occurrence that results in death, is life-threatening, requires or prolongs inpatient hospitalization (including elective surgery), results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Infection and Infestation AEs Reported During Double-Blind Treatment</measure>
    <time_frame>From start of substudy up to 56 days post last dose in the double-blind period or start of the open-label rescue period, whichever occurred first until end of study (study duration was 115 weeks)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. Infection and Infestation AEs = any AE within the System Organ Class Infection and Infestation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Malignant Neoplasms Reported During Double-Blind Treatment</measure>
    <time_frame>From start of substudy up to 56 days post last dose in the double-blind period or start of the open-label rescue period, whichever occurred first until end of study (study duration was 115 weeks)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>All neoplasms were assessed by medical review as to whether or not the event was malignant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Prespecified Acute Infusional Adverse Events (AIAEs) During Double-Blind Treatment, by Intensity</measure>
    <time_frame>From start of substudy up to 56 days post last dose in the double-blind period or start of the open-label rescue period, whichever occurred first until end of study (study duration was 115 weeks)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. Acute Infusional AE= a subset of the peri-infusional AEs with onset during the first hour after the start of the study drug infusion. A total of 105 infusional events were prespecified in the protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Prespecified Peri-Infusional Adverse Events (PAIAEs) During Double-Blind Treatment, by Intensity</measure>
    <time_frame>From start of substudy up to 56 days post last dose in the double-blind period or start of the open-label rescue period, whichever occurred first until end of study (study duration was 115 weeks)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. Peri-infusional AE=a pre-specified infusional AE occuring during the first 24 hours after the start of study drug infusion.A total of 105 infusional events were prespecified in the protocol. GDASC=General Disorders and Administration Site Conditions, RTMD=Respiratory, Thoracic and Mediastinal Disorders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Pre-specified Autoimmune Disorders (ADs) Reported During Double-Blind Treatment, by Intensity</measure>
    <time_frame>From start of substudy up to 56 days post last dose in the double-blind period or start of the open-label rescue period, whichever occurred first until end of study (study duration was 115 weeks)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>A total of 127 autoimmune disorders were prespecified in the protocol. MCTD=Musculoskeletal and Connective Tissue Disorders</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Laboratory Values Meeting the Marked Abnormality Criteria During Double-Blind Treatment</measure>
    <time_frame>From start of substudy up to 56 days post last dose in the double-blind period or start of the open-label rescue period, whichever occurred first until end of study (study duration was 115 weeks)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Not evaluated: high hemoglobin,high hematocrit,high erythrocytes,high neutrophils+bands(N+B),low monocytes,low basophils,low eosinophils,low alkaline phosphatase(ALP),low aspartate aminotransferase(AST),low alanine aminotransferase(ALT),low G-Glutamyl transferase(GGT),low total bilirubin,low blood urea nitrogen,low creatinine,high albumin,low uric acid,low urine protein,low urine glucose,low urine blood,low urine leukocyte esterase,low urine white blood cells,low red blood cells.Pre Rx=pretreatment,(*)Lymphocytes(c/uL):Low&lt;.750x10^3,High&gt;7.50x10^3.(*)Eosinophils:&gt;.750x10^3 c/uL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically Significant Changes in Vital Signs and Physical Findings</measure>
    <time_frame>From start of substudy up to 56 days post last dose in the double-blind period or start of the open-label rescue period, whichever occurred first until end of study (study duration was 115 weeks)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Clinical significance was determined by investigator. Parameters include blood pressure, heart rate, respiration rate, and temperature.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Positive Antibody Responses to Abatacept (Electrochemiluminescence [ECL] Method) During Double-Blind Treatment</measure>
    <time_frame>After 12 months of treatment</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>A positive antibody response to Abatacept (measured by the ECL assay) is further classified as a positive response for either Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) and Possibly immunoglobulin (Ig)' or 'Ig and/or Junction Region'</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">108</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Abatacept (10 mg/Kg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Abatacept (5 mg/Kg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abatacept</intervention_name>
    <description>IV solution, IV, 10 mg/Kg, Once monthly, 1 year</description>
    <arm_group_label>Abatacept (10 mg/Kg)</arm_group_label>
    <other_name>BMS-188667</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abatacept</intervention_name>
    <description>IV solution, IV, 5 mg/Kg, Once monthly, 1 year</description>
    <arm_group_label>Abatacept (5 mg/Kg)</arm_group_label>
    <other_name>BMS-188667</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who have completed the main study, are willing to participate and have a DAS
             28 ESR score of &lt; 2.6 on Day 701 of the main study

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <link>
    <url>http://ctr.bms.com/ctd/start.do</url>
    <description>BMS Clinical Trials Disclosure</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>June 2011</verification_date>
  <lastchanged_date>June 18, 2011</lastchanged_date>
  <firstreceived_date>October 2, 2009</firstreceived_date>
  <firstreceived_results_date>May 12, 2011</firstreceived_results_date>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>Bristol-Myers Squibb</organization>
  </responsible_party>
  <keyword>NOS</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Abatacept</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>IM101023 (NCT00122382) was a 2-year study completing on Day 729, in which subjects were randomized to receive abatacept or placebo in combination with methotrexate (MTX) for the 1st year of the study and were then switched to open-label abatacept+MTX in the 2nd year. All subjects had received abatacept for a least 1 year prior start of sub-study.</recruitment_details>
      <pre_assignment_details>Of the 433 participants who completed the main study (IM101-023 NCT00122382), 108 enrolled in the sub-study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Abatacept (10 mg/kg)</title>
          <description>All subjects in the sub-study randomized to receive double-blind abatacept 10 mg/kg. Subjects rescued to open-label treatment received abatacept 10 mg/kg. The length of the sub-study is 1 year. As such, the maximum time the subject is treated collectively in double-blind and open-label treatment is 1 year.</description>
        </group>
        <group group_id="P2">
          <title>Abatacept (5 mg/kg)</title>
          <description>All subjects in the sub-study randomized to receive double-blind abatacept 5 mg/kg. Subjects rescued to open-label treatment received abatacept 10 mg/kg. The length of the sub-study is 1 year. As such, the maximum time the subject is treated collectively in double-blind and open-label treatment is 1 year.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Number Rescued to Open-Label Treatment</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4">Of these, 1 was discontinued from open-label treatment (lost to follow-up).</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Number Completing Double-Blind Treatment</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal of Consent</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Desire to Become Pregnant</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized by Mistake</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Abatacept (10 mg/kg)</title>
          <description>All participants in the sub-study randomized to receive double-blind abatacept 10 mg/kg</description>
        </group>
        <group group_id="B2">
          <title>Abatacept (5 mg/kg)</title>
          <description>All participants in the sub-study randomized to receive double-blind abatacept 5 mg/kg</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="58"/>
                <measurement group_id="B2" value="50"/>
                <measurement group_id="B3" value="108"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="50.1" spread="11.5"/>
                <measurement group_id="B2" value="51.1" spread="13.4"/>
                <measurement group_id="B3" value="50.6" spread="12.3"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="44"/>
                <measurement group_id="B2" value="41"/>
                <measurement group_id="B3" value="85"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="14"/>
                <measurement group_id="B2" value="9"/>
                <measurement group_id="B3" value="23"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Unknown</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="49"/>
                <measurement group_id="B2" value="46"/>
                <measurement group_id="B3" value="95"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="2"/>
                <measurement group_id="B3" value="4"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Other</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
                <measurement group_id="B2" value="2"/>
                <measurement group_id="B3" value="5"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Weight</title>
          <description>One participant in the 10 mg/kg group did not have weight reported.</description>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="72.9" spread="14.7"/>
                <measurement group_id="B2" value="73.8" spread="16.0"/>
                <measurement group_id="B3" value="73.4" spread="15.3"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Disease Activity Scores Using C-reactive Protein (DAS 28 [CRP])</title>
          <description>The DAS28 provides a score on a scale from 0 to 10 indicating the current activity of the rheumatoid arthritis (&gt;5.1=high disease activity; &lt;3.2=low disease activity; &lt;2.6=remission).DAS 28 is a continuous variable which is a composite of 4 variables: the number of tender joints out of 28, the number of swollen joints out of 28 joints, C-reactive protein in mg/L (CRP) and subject assessment of disease activity measure on a visual analogue scale (VAS) of 100 mm based on the following formula:
DAS 28 = 0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.36*ln(CRP+1) + 0.014*GH + 0.96.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="2.1" spread="0.6"/>
                <measurement group_id="B2" value="2.1" spread="0.6"/>
                <measurement group_id="B3" value="2.1" spread="0.6"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Disease Relapse</title>
        <description>Disease relapse is defined as additional DMARD therapy given, or 2 or more courses of high steroids given, or return to abatacept 10 mg/kg (rescue medication given), or DAS28 CRP score &gt;= 3.2 at 2 consecutive visits.</description>
        <time_frame>After 12 Months of treatment</time_frame>
        <safety_issue>No</safety_issue>
        <population>Number of participants analyzed=number randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept (10 mg/kg)</title>
            <description>All participants in the sub-study randomized to receive double-blind abatacept 10 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Abatacept (5 mg/kg)</title>
            <description>All participants in the sub-study randomized to receive double-blind abatacept 5 mg/kg</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="58"/>
                  <measurement group_id="O2" value="50"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants Experiencing Disease Relapse</title>
            <description>Disease relapse is defined as additional DMARD therapy given, or 2 or more courses of high steroids given, or return to abatacept 10 mg/kg (rescue medication given), or DAS28 CRP score &gt;= 3.2 at 2 consecutive visits.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="17"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Time-Matched Baseline DAS28 CRP Scores</title>
        <description>Mean baseline DAS28 CRP values for the cohort of participants with serum samples available at that timepoint. DAS 28 is a continuous variable which is a composite of 4 variables: number of tender joints out of 28, number of swollen joints out of 28 joints, CRP in mg/L and subject assessment of disease activity measure on a visual analogue scale (VAS) of 100 mm. The DAS28 provides a score on a scale from 0 to 10 indicating the current activity of the rheumatoid arthritis (&gt;5.1=high disease activity; &lt;3.2=low disease activity; &lt;2.6=remission).</description>
        <time_frame>Baseline</time_frame>
        <safety_issue>No</safety_issue>
        <population>Number of participants analyzed=number of participants randomized; n=All treated participants with available DAS28 CRP scores at that time point. Mean time-matched baseline values reflect changing n-values over time.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept (10 mg/kg)</title>
            <description>All participants in the sub-study randomized to receive double-blind abatacept 10 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Abatacept (5 mg/kg)</title>
            <description>All participants in the sub-study randomized to receive double-blind abatacept 5 mg/kg</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="58"/>
                  <measurement group_id="O2" value="50"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Time-Matched Baseline DAS28 CRP Scores</title>
            <description>Mean baseline DAS28 CRP values for the cohort of participants with serum samples available at that timepoint. DAS 28 is a continuous variable which is a composite of 4 variables: number of tender joints out of 28, number of swollen joints out of 28 joints, CRP in mg/L and subject assessment of disease activity measure on a visual analogue scale (VAS) of 100 mm. The DAS28 provides a score on a scale from 0 to 10 indicating the current activity of the rheumatoid arthritis (&gt;5.1=high disease activity; &lt;3.2=low disease activity; &lt;2.6=remission).</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Day 29 Cohort (n=45, 40)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.09" spread="0.61"/>
                  <measurement group_id="O2" value="2.05" spread="0.60"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 57 Cohort (n=47, 37)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.06" spread="0.59"/>
                  <measurement group_id="O2" value="2.06" spread="0.62"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 85 Cohort (n=46, 42)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.10" spread="0.60"/>
                  <measurement group_id="O2" value="2.09" spread="0.60"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 113 Cohort (n=49, 39)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.06" spread="0.61"/>
                  <measurement group_id="O2" value="2.09" spread="0.62"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 141 Cohort (n=47, 40)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.09" spread="0.59"/>
                  <measurement group_id="O2" value="2.10" spread="0.62"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 169 Cohort (n=46, 36)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.10" spread="0.59"/>
                  <measurement group_id="O2" value="2.04" spread="0.61"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 197 Cohort (n=44, 38)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.08" spread="0.60"/>
                  <measurement group_id="O2" value="2.06" spread="0.61"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 225 Cohort (n=44, 38)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.09" spread="0.60"/>
                  <measurement group_id="O2" value="2.08" spread="0.63"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 253 Cohort (n=46, 37)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.07" spread="0.60"/>
                  <measurement group_id="O2" value="2.04" spread="0.61"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 281 Cohort (n=45, 38)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.07" spread="0.61"/>
                  <measurement group_id="O2" value="2.06" spread="0.61"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 309 Cohort (n=45, 37)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.10" spread="0.58"/>
                  <measurement group_id="O2" value="2.08" spread="0.61"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 337 Cohort (n=44, 36)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.09" spread="0.60"/>
                  <measurement group_id="O2" value="2.08" spread="0.62"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 365 Cohort (n=41, 35)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.02" spread="0.60"/>
                  <measurement group_id="O2" value="2.08" spread="0.60"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Change From Baseline in DAS28 CRP During Double-Blind Treatment</title>
        <description>Mean baseline DAS28 CRP values for the cohort of participants with serum samples available at that timepoint. DAS 28 is a continuous variable which is a composite of 4 variables: number of tender joints out of 28, number of swollen joints out of 28 joints, CRP in mg/L and subject assessment of disease activity measure on a VAS of 100 mm. The DAS28 provides a score on a scale from 0 to 10 indicating the current activity of the rheumatoid arthritis (&gt;5.1=high disease activity; &lt;3.2=low disease activity; &lt;2.6=remission).</description>
        <time_frame>Baseline, Days 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, 337, 365</time_frame>
        <safety_issue>No</safety_issue>
        <population>Number of participants analyzed=number of participants randomized; n=the number of participants with available DAS28 CRP scores at that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept (10 mg/kg)</title>
            <description>All participants in the sub-study randomized to receive double-blind abatacept 10 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Abatacept (5 mg/kg)</title>
            <description>All participants in the sub-study randomized to receive double-blind abatacept 5 mg/kg</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="58"/>
                  <measurement group_id="O2" value="50"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Adjusted Mean Change From Baseline in DAS28 CRP During Double-Blind Treatment</title>
            <description>Mean baseline DAS28 CRP values for the cohort of participants with serum samples available at that timepoint. DAS 28 is a continuous variable which is a composite of 4 variables: number of tender joints out of 28, number of swollen joints out of 28 joints, CRP in mg/L and subject assessment of disease activity measure on a VAS of 100 mm. The DAS28 provides a score on a scale from 0 to 10 indicating the current activity of the rheumatoid arthritis (&gt;5.1=high disease activity; &lt;3.2=low disease activity; &lt;2.6=remission).</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <sub_title>Day 29 (n=45, 40)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.24" spread="0.10"/>
                  <measurement group_id="O2" value="0.06" spread="0.10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 57 (n=47, 37)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.05" spread="0.09"/>
                  <measurement group_id="O2" value="0.14" spread="0.10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 85 (n=46, 42)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.13" spread="0.10"/>
                  <measurement group_id="O2" value="0.21" spread="0.10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 113 (n=49, 39)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.02" spread="0.09"/>
                  <measurement group_id="O2" value="0.25" spread="0.10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 141 (n=47, 40)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.32" spread="0.10"/>
                  <measurement group_id="O2" value="0.29" spread="0.11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 169 (n=46, 36)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.13" spread="0.09"/>
                  <measurement group_id="O2" value="0.26" spread="0.11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 197 (n=44, 38)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.09" spread="0.09"/>
                  <measurement group_id="O2" value="0.22" spread="0.09"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 225 (n=44, 38)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.25" spread="0.10"/>
                  <measurement group_id="O2" value="0.29" spread="0.10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 253 (n=46, 37)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.23" spread="0.09"/>
                  <measurement group_id="O2" value="0.14" spread="0.10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 281 (n=45, 38)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.18" spread="0.08"/>
                  <measurement group_id="O2" value="0.05" spread="0.09"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 309 (n=45, 37)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.07" spread="0.08"/>
                  <measurement group_id="O2" value="0.09" spread="0.09"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 337 (n=44, 36)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.26" spread="0.11"/>
                  <measurement group_id="O2" value="0.29" spread="0.13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 365 (n=41, 35)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.39" spread="0.11"/>
                  <measurement group_id="O2" value="0.16" spread="0.12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 29</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>Adjusted difference</param_type>
            <param_value>0.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.11</ci_lower_limit>
            <ci_upper_limit>0.46</ci_upper_limit>
            <estimate_desc>Change from Baseline = Post-baseline - Baseline value.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 57</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>Adjusted Difference</param_type>
            <param_value>-0.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.34</ci_lower_limit>
            <ci_upper_limit>0.17</ci_upper_limit>
            <estimate_desc>Change from Baseline = Post-baseline - Baseline value.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 85</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>Adjusted Difference</param_type>
            <param_value>-0.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.37</ci_lower_limit>
            <ci_upper_limit>0.20</ci_upper_limit>
            <estimate_desc>Change from Baseline = Post-baseline - Baseline value.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 113</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>Adjusted Difference</param_type>
            <param_value>-0.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.50</ci_lower_limit>
            <ci_upper_limit>0.04</ci_upper_limit>
            <estimate_desc>Change from Baseline = Post-baseline - Baseline value.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 141</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>Adjusted Difference</param_type>
            <param_value>0.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.26</ci_lower_limit>
            <ci_upper_limit>0.32</ci_upper_limit>
            <estimate_desc>Change from Baseline = Post-baseline - Baseline value.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 169</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>Adjusted Difference</param_type>
            <param_value>-0.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.41</ci_lower_limit>
            <ci_upper_limit>0.15</ci_upper_limit>
            <estimate_desc>Change from Baseline = Post-baseline - Baseline value.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 197</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>Adjusted Difference</param_type>
            <param_value>-0.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.38</ci_lower_limit>
            <ci_upper_limit>0.13</ci_upper_limit>
            <estimate_desc>Change from Baseline = Post-baseline - Baseline value.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 225</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>Adjusted Difference</param_type>
            <param_value>-0.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.32</ci_lower_limit>
            <ci_upper_limit>0.25</ci_upper_limit>
            <estimate_desc>Change from Baseline = Post-baseline - Baseline value.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 253</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>Adjusted Difference</param_type>
            <param_value>0.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.19</ci_lower_limit>
            <ci_upper_limit>0.36</ci_upper_limit>
            <estimate_desc>Change from Baseline = Post-baseline - Baseline value.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 281</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>Adjusted Difference</param_type>
            <param_value>0.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.12</ci_lower_limit>
            <ci_upper_limit>0.38</ci_upper_limit>
            <estimate_desc>Change from Baseline = Post-baseline - Baseline value.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 309</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>Adjusted Difference</param_type>
            <param_value>-0.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.27</ci_lower_limit>
            <ci_upper_limit>0.22</ci_upper_limit>
            <estimate_desc>Change from Baseline = Post-baseline - Baseline value.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 337</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>Adjusted Difference</param_type>
            <param_value>-0.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.37</ci_lower_limit>
            <ci_upper_limit>0.31</ci_upper_limit>
            <estimate_desc>Change from Baseline = Post-baseline - Baseline value.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 365</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>Adjusted Difference</param_type>
            <param_value>0.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.09</ci_lower_limit>
            <ci_upper_limit>0.55</ci_upper_limit>
            <estimate_desc>Change from Baseline = Post-baseline - Baseline value.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With 2 Consecutive DAS 28 CRP Scores ≥ 3.2 (Loss of Low Disease Activity Status)</title>
        <description>DAS 28 is a continuous variable which is a composite of 4 variables: number of tender joints out of 28, number of swollen joints out of 28 joints, CRP in mg/L and subject assessment of disease activity measure on a VAS of 100 mm. The DAS28 provides a score on a scale from 0 to 10 indicating the current activity of the rheumatoid arthritis (&gt;5.1=high disease activity; &lt;3.2=low disease activity; &lt;2.6=remission).</description>
        <time_frame>After 12 months of treatment</time_frame>
        <safety_issue>No</safety_issue>
        <population>Number of participants analyzed= number of participants randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept (10 mg/kg)</title>
            <description>All participants in the sub-study randomized to receive double-blind abatacept 10 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Abatacept (5 mg/kg)</title>
            <description>All participants in the sub-study randomized to receive double-blind abatacept 5 mg/kg</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="58"/>
                  <measurement group_id="O2" value="50"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Participants With 2 Consecutive DAS 28 CRP Scores ≥ 3.2 (Loss of Low Disease Activity Status)</title>
            <description>DAS 28 is a continuous variable which is a composite of 4 variables: number of tender joints out of 28, number of swollen joints out of 28 joints, CRP in mg/L and subject assessment of disease activity measure on a VAS of 100 mm. The DAS28 provides a score on a scale from 0 to 10 indicating the current activity of the rheumatoid arthritis (&gt;5.1=high disease activity; &lt;3.2=low disease activity; &lt;2.6=remission).</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="22.4" lower_limit="11.7" upper_limit="33.1"/>
                  <measurement group_id="O2" value="22.0" lower_limit="10.5" upper_limit="33.5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <param_type>estimate of difference</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.2</ci_lower_limit>
            <ci_upper_limit>18.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Given Additional DMARD Therapy During Double-Blind Treatment</title>
        <description>Additional DMARD therapy is defined as a re-introduction of methotrexate (MTX), an increase of at least 2.5 mg of MTX, or the addition of at least 1 DMARD.</description>
        <time_frame>After 12 months of treatment</time_frame>
        <safety_issue>No</safety_issue>
        <population>Number of participants analyzed= number of participants randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept (10 mg/kg)</title>
            <description>All participants in the sub-study randomized to receive double-blind abatacept 10 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Abatacept (5 mg/kg)</title>
            <description>All participants in the sub-study randomized to receive double-blind abatacept 5 mg/kg</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="58"/>
                  <measurement group_id="O2" value="50"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Participants Given Additional DMARD Therapy During Double-Blind Treatment</title>
            <description>Additional DMARD therapy is defined as a re-introduction of methotrexate (MTX), an increase of at least 2.5 mg of MTX, or the addition of at least 1 DMARD.</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="3.4" lower_limit="-1.2" upper_limit="8.1"/>
                  <measurement group_id="O2" value="12.0" lower_limit="3.0" upper_limit="21.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <param_type>estimate of difference</param_type>
            <param_value>-8.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-20.3</ci_lower_limit>
            <ci_upper_limit>3.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who at Any Time During Double-Blind Treatment Were Given 2 or More Courses of High-Dose Steroids</title>
        <description>A course of high dose steroids is defined as a course of intramuscular, intravenous, or high dose oral corticosteroids (use of &gt; 10 mg/day equivalent of prednisone for a minimum of 3 consecutive days or for those subjects who had continued use for long durations of time, each course was determined by 28 day intervals).</description>
        <time_frame>After 12 months of treatment</time_frame>
        <safety_issue>No</safety_issue>
        <population>Number of participants analyzed= number of participants randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept (10 mg/kg)</title>
            <description>All participants in the sub-study randomized to receive double-blind abatacept 10 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Abatacept (5 mg/kg)</title>
            <description>All participants in the sub-study randomized to receive double-blind abatacept 5 mg/kg</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="58"/>
                  <measurement group_id="O2" value="50"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Participants Who at Any Time During Double-Blind Treatment Were Given 2 or More Courses of High-Dose Steroids</title>
            <description>A course of high dose steroids is defined as a course of intramuscular, intravenous, or high dose oral corticosteroids (use of &gt; 10 mg/day equivalent of prednisone for a minimum of 3 consecutive days or for those subjects who had continued use for long durations of time, each course was determined by 28 day intervals).</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                  <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Disease Relapse Through Month 12 (Kaplan-Meier Cumulative Percentage of Events of Disease Relapse)</title>
        <description>An event of disease relapse was defined as additional Disease-modifying antirheumatic drug (DMARD) therapy given, or 2 or more courses of high steroids given, or return to abatacept 10 mg/kg (rescue medication given), or DAS28 C-reactive protein (CRP) score &gt;=3.2 at 2 consecutive visits. Time to disease relapse was evaluated using life tables (Kaplan-Meier Cumulative Percentage of Events of Disease Relapse).</description>
        <time_frame>Months 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12</time_frame>
        <safety_issue>No</safety_issue>
        <population>Number of participants analyzed=number of participants randomized. n=number of participants at risk at the end of a specified month.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept (10 mg/kg)</title>
            <description>All participants in the sub-study randomized to receive double-blind abatacept 10 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Abatacept (5 mg/kg)</title>
            <description>All participants in the sub-study randomized to receive double-blind abatacept 5 mg/kg</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="58"/>
                  <measurement group_id="O2" value="50"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Time to Disease Relapse Through Month 12 (Kaplan-Meier Cumulative Percentage of Events of Disease Relapse)</title>
            <description>An event of disease relapse was defined as additional Disease-modifying antirheumatic drug (DMARD) therapy given, or 2 or more courses of high steroids given, or return to abatacept 10 mg/kg (rescue medication given), or DAS28 C-reactive protein (CRP) score &gt;=3.2 at 2 consecutive visits. Time to disease relapse was evaluated using life tables (Kaplan-Meier Cumulative Percentage of Events of Disease Relapse).</description>
            <units>Percentage of Events</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Month 1 (n=55, 49)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.17"/>
                  <measurement group_id="O2" value="2.00"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 2 (n=52, 47)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8.65"/>
                  <measurement group_id="O2" value="4.00"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 3 (n=51, 42)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10.41"/>
                  <measurement group_id="O2" value="12.35"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 4 (n=50, 38)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12.17"/>
                  <measurement group_id="O2" value="22.78"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 5 (n=47, 35)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13.96"/>
                  <measurement group_id="O2" value="26.96"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 6 (n=42, 33)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="23.11"/>
                  <measurement group_id="O2" value="31.13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 7 (n=41, 32)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="24.94"/>
                  <measurement group_id="O2" value="33.22"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 8 (n=40, 31)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="26.77"/>
                  <measurement group_id="O2" value="33.22"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 9 (n=38, 31)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="30.43"/>
                  <measurement group_id="O2" value="33.22"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 10 (n=37, 31)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="32.27"/>
                  <measurement group_id="O2" value="33.22"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 11 (n=37, 30)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="32.27"/>
                  <measurement group_id="O2" value="35.37"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 12 (n=36, 28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="32.27"/>
                  <measurement group_id="O2" value="35.37"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Through Month 12</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.870</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.45</ci_lower_limit>
            <ci_upper_limit>1.69</ci_upper_limit>
            <estimate_desc>Hazard ratio determined by a Cox proportional hazards model with treatment as the only covariate.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Given Rescue Medication Therapy During Double-Blind Treatment</title>
        <description>All subjects in the sub-study randomized to receive double-blind abatacept 5 mg/kg or 10 mg/kg. Subjects rescued to open-label treatment received abatacept 10 mg/kg.</description>
        <time_frame>After 12 months of treatment</time_frame>
        <safety_issue>No</safety_issue>
        <population>Number of participants analyzed= number of participants randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept (10 mg/kg)</title>
            <description>All participants in the sub-study randomized to receive double-blind abatacept 10 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Abatacept (5 mg/kg)</title>
            <description>All participants in the sub-study randomized to receive double-blind abatacept 5 mg/kg</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="58"/>
                  <measurement group_id="O2" value="50"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Participants Given Rescue Medication Therapy During Double-Blind Treatment</title>
            <description>All subjects in the sub-study randomized to receive double-blind abatacept 5 mg/kg or 10 mg/kg. Subjects rescued to open-label treatment received abatacept 10 mg/kg.</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="6.9" lower_limit="0.4" upper_limit="13.4"/>
                  <measurement group_id="O2" value="8.0" lower_limit="0.5" upper_limit="15.5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <param_type>estimate of difference</param_type>
            <param_value>-1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.9</ci_lower_limit>
            <ci_upper_limit>10.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Modified Therapy During Double-Blind Treatment</title>
        <description>Modified therapy=additional DMARD therapy, 2 or more courses of high dose steroids or rescue medication. Additional DMARD therapy=re-introduction of methotrexate (MTX), an increase of at least 2.5 mg of MTX, or the addition of at least 1 DMARD. A course of high dose steroids=a course of intramuscular, intravenous, or high dose oral corticosteroids (use of &gt; 10 mg/day equivalent of prednisone for a minimum of 3 consecutive days or for those subjects who had continued use for long durations of time, each course was determined by 28 day intervals). Rescue medication=abatacept 10 mg/kg.</description>
        <time_frame>After 12 months of treatment</time_frame>
        <safety_issue>No</safety_issue>
        <population>Number of participants analyzed= number of participants randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept (10 mg/kg)</title>
            <description>All participants in the sub-study randomized to receive double-blind abatacept 10 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Abatacept (5 mg/kg)</title>
            <description>All participants in the sub-study randomized to receive double-blind abatacept 5 mg/kg</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="58"/>
                  <measurement group_id="O2" value="50"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Participants Who Modified Therapy During Double-Blind Treatment</title>
            <description>Modified therapy=additional DMARD therapy, 2 or more courses of high dose steroids or rescue medication. Additional DMARD therapy=re-introduction of methotrexate (MTX), an increase of at least 2.5 mg of MTX, or the addition of at least 1 DMARD. A course of high dose steroids=a course of intramuscular, intravenous, or high dose oral corticosteroids (use of &gt; 10 mg/day equivalent of prednisone for a minimum of 3 consecutive days or for those subjects who had continued use for long durations of time, each course was determined by 28 day intervals). Rescue medication=abatacept 10 mg/kg.</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10.3" lower_limit="2.5" upper_limit="18.2"/>
                  <measurement group_id="O2" value="18.0" lower_limit="7.4" upper_limit="28.6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <param_type>estimate of difference</param_type>
            <param_value>-7.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.6</ci_lower_limit>
            <ci_upper_limit>7.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Lost Remission Status</title>
        <description>Loss of remission is defined as DAS 28 CRP &gt;=2.6.</description>
        <time_frame>After 12 months of treatment</time_frame>
        <safety_issue>No</safety_issue>
        <population>Number of participants analyzed= number of participants randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept (10 mg/kg)</title>
            <description>All participants in the sub-study randomized to receive double-blind abatacept 10 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Abatacept (5 mg/kg)</title>
            <description>All participants in the sub-study randomized to receive double-blind abatacept 5 mg/kg</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="58"/>
                  <measurement group_id="O2" value="50"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Participants Who Lost Remission Status</title>
            <description>Loss of remission is defined as DAS 28 CRP &gt;=2.6.</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="53.4" lower_limit="40.6" upper_limit="66.3"/>
                  <measurement group_id="O2" value="64.0" lower_limit="50.7" upper_limit="77.3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <param_type>estimate of difference</param_type>
            <param_value>-10.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-31.1</ci_lower_limit>
            <ci_upper_limit>10.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Steady-state Trough Serum Concentration (Cmin) of Abatacept During Double-Blind Treatment</title>
        <time_frame>Day 701 of the main study; sub-study Days 1, 85, 169, 253</time_frame>
        <safety_issue>No</safety_issue>
        <population>Number of participants analyzed= number of participants randomized; n =randomized participants with measurement at given time point. For the Day 701 measure, one apparent outlier sample was deleted..</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept (10 mg/kg)</title>
            <description>All participants in the sub-study randomized to receive double-blind abatacept 10 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Abatacept (5 mg/kg)</title>
            <description>All participants in the sub-study randomized to receive double-blind abatacept 5 mg/kg</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="58"/>
                  <measurement group_id="O2" value="50"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Steady-state Trough Serum Concentration (Cmin) of Abatacept During Double-Blind Treatment</title>
            <units>ng/mL</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Main Study Day 701 (n=41, 36)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="22992.0" spread="9722.1"/>
                  <measurement group_id="O2" value="21713.5" spread="9520.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sub-Study Day 1 (n=46, 41)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="22213.0" spread="9275.8"/>
                  <measurement group_id="O2" value="23620.7" spread="9648.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sub-Study Day 85 (n=47, 43)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="24919.5" spread="14516.2"/>
                  <measurement group_id="O2" value="11922.1" spread="5681.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sub-Study Day 169 (n=48, 43)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="25725.7" spread="18500.5"/>
                  <measurement group_id="O2" value="9959.2" spread="5045.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sub-Study Day 253 (n=47, 42)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="28524.7" spread="19989.9"/>
                  <measurement group_id="O2" value="13516.2" spread="6564.6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths, and Discontinuations During Double-Blind Treatment</title>
        <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. Related AE/SAE=Certain, Probable, Possible, or Missing. SAE=any untoward medical occurrence that results in death, is life-threatening, requires or prolongs inpatient hospitalization (including elective surgery), results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.</description>
        <time_frame>From start of substudy up to 56 days post last dose in the double-blind period or start of the open-label rescue period, whichever occurred first until end of study (study duration was 115 weeks)</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Number of participants analyzed = All treated participants during the double-blind period.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept (10 mg/kg)</title>
            <description>All participants in the sub-study treated with double-blind abatacept 10 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Abatacept (5 mg/kg)</title>
            <description>All participants in the sub-study treated with double-blind abatacept 5 mg/kg</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="58"/>
                  <measurement group_id="O2" value="50"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths, and Discontinuations During Double-Blind Treatment</title>
            <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. Related AE/SAE=Certain, Probable, Possible, or Missing. SAE=any untoward medical occurrence that results in death, is life-threatening, requires or prolongs inpatient hospitalization (including elective surgery), results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Deaths</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>SAEs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.2"/>
                  <measurement group_id="O2" value="6.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related SAEs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.7"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Discontinued due to SAEs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AEs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="65.5"/>
                  <measurement group_id="O2" value="50.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related AEs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20.7"/>
                  <measurement group_id="O2" value="10.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Discontinued due to AEs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Infection and Infestation AEs Reported During Double-Blind Treatment</title>
        <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. Infection and Infestation AEs = any AE within the System Organ Class Infection and Infestation.</description>
        <time_frame>From start of substudy up to 56 days post last dose in the double-blind period or start of the open-label rescue period, whichever occurred first until end of study (study duration was 115 weeks)</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Number of participants analyzed = All treated participants during the double-blind period.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept (10 mg/kg)</title>
            <description>All participants in the sub-study treated with double-blind abatacept 10 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Abatacept (5 mg/kg)</title>
            <description>All participants in the sub-study treated with double-blind abatacept 5 mg/kg</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="58"/>
                  <measurement group_id="O2" value="50"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Participants With Infection and Infestation AEs Reported During Double-Blind Treatment</title>
            <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. Infection and Infestation AEs = any AE within the System Organ Class Infection and Infestation.</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Total Participants with Infection and Infestation</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="37.9"/>
                  <measurement group_id="O2" value="26.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.2"/>
                  <measurement group_id="O2" value="12.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Nasopharyngitis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.2"/>
                  <measurement group_id="O2" value="6.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Influenza</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.2"/>
                  <measurement group_id="O2" value="4.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Bronchitis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.2"/>
                  <measurement group_id="O2" value="2.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urinary Tract Infection</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.4"/>
                  <measurement group_id="O2" value="4.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Onychomycosis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.4"/>
                  <measurement group_id="O2" value="2.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pharyngitis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.4"/>
                  <measurement group_id="O2" value="2.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Rhinitis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.4"/>
                  <measurement group_id="O2" value="2.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Ear Infection</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.4"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Vaginal Infection</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.4"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Appendicitis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.7"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Furuncle</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.7"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pneumonia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.7"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sinusitis Bacterial</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.7"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Endocarditis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fungal Skin Infection</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Herpes Simplex</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Labyrinthitis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Oral Herpes</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Respiratory Tract Infection</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sinusitis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Malignant Neoplasms Reported During Double-Blind Treatment</title>
        <description>All neoplasms were assessed by medical review as to whether or not the event was malignant.</description>
        <time_frame>From start of substudy up to 56 days post last dose in the double-blind period or start of the open-label rescue period, whichever occurred first until end of study (study duration was 115 weeks)</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Number of participants analyzed = All treated participants during the double-blind period.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept (10 mg/kg)</title>
            <description>All participants in the sub-study treated with double-blind abatacept 10 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Abatacept (5 mg/kg)</title>
            <description>All participants in the sub-study treated with double-blind abatacept 5 mg/kg</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="58"/>
                  <measurement group_id="O2" value="50"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Participants With Malignant Neoplasms Reported During Double-Blind Treatment</title>
            <description>All neoplasms were assessed by medical review as to whether or not the event was malignant.</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Prespecified Acute Infusional Adverse Events (AIAEs) During Double-Blind Treatment, by Intensity</title>
        <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. Acute Infusional AE= a subset of the peri-infusional AEs with onset during the first hour after the start of the study drug infusion. A total of 105 infusional events were prespecified in the protocol.</description>
        <time_frame>From start of substudy up to 56 days post last dose in the double-blind period or start of the open-label rescue period, whichever occurred first until end of study (study duration was 115 weeks)</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Number of participants analyzed = All treated participants during the double-blind period.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept (10 mg/kg)</title>
            <description>All participants in the sub-study treated with double-blind abatacept 10 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Abatacept (5 mg/kg)</title>
            <description>All participants in the sub-study treated with double-blind abatacept 5 mg/kg</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="58"/>
                  <measurement group_id="O2" value="50"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Participants With Prespecified Acute Infusional Adverse Events (AIAEs) During Double-Blind Treatment, by Intensity</title>
            <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. Acute Infusional AE= a subset of the peri-infusional AEs with onset during the first hour after the start of the study drug infusion. A total of 105 infusional events were prespecified in the protocol.</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Total Participants with AIAEs (mild)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total Participants with AIAEs (moderate)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total Participants with AIAEs (severe)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total Participants with AIAEs (very severe)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Vascular Disorders - Hypertension (mild)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Vascular Disorders - Hypertension (moderate)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Vascular Disorders - Hypertension (severe)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Vascular Disorders - Hypertension (very severe)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Vascular Disorders - Hypertension (unknown)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Prespecified Peri-Infusional Adverse Events (PAIAEs) During Double-Blind Treatment, by Intensity</title>
        <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. Peri-infusional AE=a pre-specified infusional AE occuring during the first 24 hours after the start of study drug infusion.A total of 105 infusional events were prespecified in the protocol. GDASC=General Disorders and Administration Site Conditions, RTMD=Respiratory, Thoracic and Mediastinal Disorders.</description>
        <time_frame>From start of substudy up to 56 days post last dose in the double-blind period or start of the open-label rescue period, whichever occurred first until end of study (study duration was 115 weeks)</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Number of participants analyzed = All treated participants during the double-blind period.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept (10 mg/kg)</title>
            <description>All participants in the sub-study treated with double-blind abatacept 10 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Abatacept (5 mg/kg)</title>
            <description>All participants in the sub-study treated with double-blind abatacept 5 mg/kg</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="58"/>
                  <measurement group_id="O2" value="50"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Participants With Prespecified Peri-Infusional Adverse Events (PAIAEs) During Double-Blind Treatment, by Intensity</title>
            <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. Peri-infusional AE=a pre-specified infusional AE occuring during the first 24 hours after the start of study drug infusion.A total of 105 infusional events were prespecified in the protocol. GDASC=General Disorders and Administration Site Conditions, RTMD=Respiratory, Thoracic and Mediastinal Disorders.</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Total Participants with PIAEs (mild)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6.9"/>
                  <measurement group_id="O2" value="4.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total Participants with PIAEs (moderate)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.7"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total Participants with PIAEs (severe)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total Participants with PIAEs (very severe)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Gastrointestinal Disorders, Nausea (mild)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.7"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Gastrointestinal Disorders, Nausea (moderate)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Gastrointestinal Disorders, Nausea (severe)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Gastrointestinal Disorders, Nausea (very severe)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Gastrointestinal Disorders, Vomiting (mild)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.7"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Gastrointestinal Disorders, Vomiting (moderate)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Gastrointestinal Disorders, Vomiting (severe)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Gastrointestinal Disorders, Vomiting (very severe)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Nervous System Disorders, Dizziness (mild)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.7"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Nervous System Disorders, Dizziness (moderate)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Nervous System Disorders, Dizziness (severe)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Nervous System Disorders, Dizziness (very severe)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Nervous System Disorders, Headache (mild)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Nervous System Disorders, Headache (moderate)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.7"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Nervous System Disorders, Headache (severe)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Nervous System Disorders, Headache (very severe)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>GDASC, Malaise (mild)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.7"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>GDASC, Malaise (moderate)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>GDASC, Malaise (severe)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>GDASC, Malaise (very severe)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>GDASC, Chest Pain (mild)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>GDASC, Chest Pain (moderate)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>GDASC, Chest Pain (severe)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>GDASC, Chest Pain (very severe)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RTMD, Asthma (mild)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.7"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RTMD, Asthma (moderate)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RTMD, Asthma (severe)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RTMD, Asthma (very severe)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RTMD, Cough (mild)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.7"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RTMD, Cough (moderate)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RTMD, Cough (severe)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RTMD, Cough (very severe)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Vascular Disorders, Hypertension (mild)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Vascular Disorders, Hypertension (moderate)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Vascular Disorders, Hypertension (severe)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Vascular Disorders, Hypertension (very severe)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Pre-specified Autoimmune Disorders (ADs) Reported During Double-Blind Treatment, by Intensity</title>
        <description>A total of 127 autoimmune disorders were prespecified in the protocol. MCTD=Musculoskeletal and Connective Tissue Disorders</description>
        <time_frame>From start of substudy up to 56 days post last dose in the double-blind period or start of the open-label rescue period, whichever occurred first until end of study (study duration was 115 weeks)</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Number of participants analyzed = All treated participants during the double-blind period.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept (10 mg/kg)</title>
            <description>All participants in the sub-study treated with double-blind abatacept 10 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Abatacept (5 mg/kg)</title>
            <description>All participants in the sub-study treated with double-blind abatacept 5 mg/kg</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="58"/>
                  <measurement group_id="O2" value="50"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Participants With Pre-specified Autoimmune Disorders (ADs) Reported During Double-Blind Treatment, by Intensity</title>
            <description>A total of 127 autoimmune disorders were prespecified in the protocol. MCTD=Musculoskeletal and Connective Tissue Disorders</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Total Participants with ADs (mild)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="4.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total Participants with ADs (moderate)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total Participants with ADs (severe)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total Participants with ADs (very severe)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Eye Disorders - Episcleritis (mild)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Eye Disorders - Episcleritis (moderate)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Eye Disorders - Episcleritis (severe)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Eye Disorders - Episcleritis (very severe)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MCTDs - Sjogren's Syndrome (mild)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MCTDs - Sjogren's Syndrome (moderate)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MCTDs - Sjogren's Syndrome (severe)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MCTDs - Sjogren's Syndrome (very severe)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Laboratory Values Meeting the Marked Abnormality Criteria During Double-Blind Treatment</title>
        <description>Not evaluated: high hemoglobin,high hematocrit,high erythrocytes,high neutrophils+bands(N+B),low monocytes,low basophils,low eosinophils,low alkaline phosphatase(ALP),low aspartate aminotransferase(AST),low alanine aminotransferase(ALT),low G-Glutamyl transferase(GGT),low total bilirubin,low blood urea nitrogen,low creatinine,high albumin,low uric acid,low urine protein,low urine glucose,low urine blood,low urine leukocyte esterase,low urine white blood cells,low red blood cells.Pre Rx=pretreatment,(*)Lymphocytes(c/uL):Low&lt;.750x10^3,High&gt;7.50x10^3.(*)Eosinophils:&gt;.750x10^3 c/uL.</description>
        <time_frame>From start of substudy up to 56 days post last dose in the double-blind period or start of the open-label rescue period, whichever occurred first until end of study (study duration was 115 weeks)</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Number of participants analyzed = All treated participants during the double-blind period; n=number of participants with specific measure</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept (10 mg/kg)</title>
            <description>All participants in the sub-study treated with double-blind abatacept 10 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Abatacept (5 mg/kg)</title>
            <description>All participants in the sub-study treated with double-blind abatacept 5 mg/kg</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="58"/>
                  <measurement group_id="O2" value="50"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Participants With Laboratory Values Meeting the Marked Abnormality Criteria During Double-Blind Treatment</title>
            <description>Not evaluated: high hemoglobin,high hematocrit,high erythrocytes,high neutrophils+bands(N+B),low monocytes,low basophils,low eosinophils,low alkaline phosphatase(ALP),low aspartate aminotransferase(AST),low alanine aminotransferase(ALT),low G-Glutamyl transferase(GGT),low total bilirubin,low blood urea nitrogen,low creatinine,high albumin,low uric acid,low urine protein,low urine glucose,low urine blood,low urine leukocyte esterase,low urine white blood cells,low red blood cells.Pre Rx=pretreatment,(*)Lymphocytes(c/uL):Low&lt;.750x10^3,High&gt;7.50x10^3.(*)Eosinophils:&gt;.750x10^3 c/uL.</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Hemoglobin, Low: &gt;3 g/dL ↓ from pre rx (n=51, 48)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hematocrit, Low: &lt;0.75 x pre rx (n=51, 48)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Erythrocytes, Low: &lt;0.75 x pre rx (n=51, 48)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALP, High: &gt;2 x upper limit normal (ULN)(n=52, 47)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total Calcium, Low: &lt;0.8 x Lower LN(LLN)(n=52, 47)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Platelet Count, Low: &lt;0.67 x LLN (n=51, 48)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Platelet Count, High: &gt;1.5 x ULN (n=51, 48)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Leukocytes, Low: &lt;0.75 x LLN (n=51, 48)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>N+B (absolute), Low: &lt; 1.00 x 10^3 c/uL (n=55, 49)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Lymphocytes (absolute), Low (*) (n=55, 49)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.8"/>
                  <measurement group_id="O2" value="2.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Lymphocytes (absolute), High (*) (n=55, 49)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Monocytes (absolute), High: &gt;2000/mm^3 (n=55, 49)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Basophils (absolute), High: &gt; 400/mm^3 (n=55, 49)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Eosinophils (absolute), High (*) (n=55, 49)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.5"/>
                  <measurement group_id="O2" value="2.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AST, High: &gt;3 x ULN (n=52, 47)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT, High: &gt;3 x ULN (n=52, 47)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>GGT, High: &gt;2 x ULN (n=52, 47)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Bilirubin Total, High: &gt;1.5 x ULN (n=52, 46)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Blood Urea Nitrogen, High: &gt;2 x pre rx (n=52, 47)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Serum Sodium, Low: &lt;0.95 x LLN (n=52, 47)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Serum Sodium, High: &gt;1.05 x ULN, (n=52, 47)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Serum Potassium, Low: &lt;0.9 x LLN (n=52, 47)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Serum Potassium, High: &gt;1.1 x ULN (n=52, 47)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Serum Chloride, Low: &lt;0.9 x LLN (n=52, 47)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Serum Chloride, High: &gt;1.1 x ULN, (n=52, 47)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total Calcium, High: &gt;1.2 x ULN (n=52, 47)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Inorganic Phosphorus, Low: &lt;0.75 x LLN (n=52, 47)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Inorganic Phosphorus, High: &gt;1.25 x ULN (n=52, 47)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Serum Glucose, Low: &lt;65 mg/dL (n=55, 48)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.5"/>
                  <measurement group_id="O2" value="6.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Serum Glucose, High: &gt;220 mg/dL (n=55, 48)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.6"/>
                  <measurement group_id="O2" value="4.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total Protein, Low: &lt;0.9 x LLN (n=52, 47)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total Protein, High: &gt;1.1 x ULN (n=52, 47)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Albumin, Low: &lt;0.9 x LLN (n=52, 47)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Uric Acid, High: &gt;1.5 x ULN (n=52, 47)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Protein, High: &gt;=2-4 (n=55, 47)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.8"/>
                  <measurement group_id="O2" value="6.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Glucose, High: &gt;=2-4 (n=55, 47)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.5"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Blood, High: &gt;=2-4 (n=55, 47)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12.7"/>
                  <measurement group_id="O2" value="10.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Leukocyte Esterase, High: &gt;=2-4 (n=20, 16)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15.0"/>
                  <measurement group_id="O2" value="25.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine White Blood Cells, High: &gt;=2-4 (n=22, 14)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="45.5"/>
                  <measurement group_id="O2" value="14.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Red Blood Cells, High: &gt;=2-4 (n=22, 14)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="22.7"/>
                  <measurement group_id="O2" value="28.6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinically Significant Changes in Vital Signs and Physical Findings</title>
        <description>Clinical significance was determined by investigator. Parameters include blood pressure, heart rate, respiration rate, and temperature.</description>
        <time_frame>From start of substudy up to 56 days post last dose in the double-blind period or start of the open-label rescue period, whichever occurred first until end of study (study duration was 115 weeks)</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>This analysis was not done because clinically significant changes in vital signs and physical findings were reported as adverse events.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept (10 mg/kg)</title>
            <description>All participants in the sub-study treated with double-blind abatacept 10 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Abatacept (5 mg/kg)</title>
            <description>All participants in the sub-study treated with double-blind abatacept 5 mg/kg</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Clinically Significant Changes in Vital Signs and Physical Findings</title>
            <description>Clinical significance was determined by investigator. Parameters include blood pressure, heart rate, respiration rate, and temperature.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1"/>
                  <measurement group_id="O2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Positive Antibody Responses to Abatacept (Electrochemiluminescence [ECL] Method) During Double-Blind Treatment</title>
        <description>A positive antibody response to Abatacept (measured by the ECL assay) is further classified as a positive response for either Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) and Possibly immunoglobulin (Ig)' or 'Ig and/or Junction Region'</description>
        <time_frame>After 12 months of treatment</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Number of participants analyzed= Number of participants with available immunogenicity measurements</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept (10 mg/kg)</title>
            <description>All participants in the sub-study treated with double-blind abatacept 10 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Abatacept (5 mg/kg)</title>
            <description>All participants in the sub-study treated with double-blind abatacept 5 mg/kg</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="56"/>
                  <measurement group_id="O2" value="49"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Participants With Positive Antibody Responses to Abatacept (Electrochemiluminescence [ECL] Method) During Double-Blind Treatment</title>
            <description>A positive antibody response to Abatacept (measured by the ECL assay) is further classified as a positive response for either Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) and Possibly immunoglobulin (Ig)' or 'Ig and/or Junction Region'</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>CTLA4 and Possibly IG</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IG and/or Junction Region</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Abatacept 5mg/kg (ST)</title>
        </group>
        <group group_id="E2">
          <title>Abatacept 10mg/kg (ST)</title>
        </group>
        <group group_id="E3">
          <title>Abatacept 10mg/kg (Open-Label)</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiopulmonary Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes Mellitus Inadequate Control</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acquired Claw Toe</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Rheumatoid Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Xerophtalmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hiatus Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Fibrocystic Breast Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>BMS Study Director</name_or_title>
      <organization>Bristol-Myers Squibb</organization>
      <email>Clinical.Trials@bms.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
